CClinicalTrials.gg
CompletedNCT07128628Updated Jul 14, 2026

A Study Evaluating the Safety and Efficacy of a Fixed-Dose Combination for Dry Eye Disease

A Phase 2 interventional study of Lifitegrast/Perfluorohexyloctane Fixed Dose Combination and Lifitegrast in Dry Eye Disease, sponsored by Bausch & Lomb Incorporated. Completed at 32 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-14.

Sponsored by Bausch & Lomb Incorporated · Phase 2, Interventional, and Treatment

Phase
Phase 2
Study type
Interventional
Enrollment
443
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

A 4-Week, Randomized, Double-Masked, Parallel-Group, Active-Controlled, Multicenter Study Evaluating Lifitegrast/Perfluorohexyloctane Fixed-Dose Combination Administered Twice Daily on Signs and Symptoms of Dry Eye Disease

02

Conditions studied

  • Dry Eye Disease

Browse trials for

03

In context

Dry Eye Syndromes

1,292 studies on the registry are indexed under Dry Eye Syndromes; 191 are open to participants now.

This study's enrollment of 443 is above the median of 60 across 1,077 interventional studies indexed under Dry Eye Syndromes.

Browse Dry Eye Syndromes studies →

Lead sponsor

Bausch & Lomb Incorporated is the lead sponsor of 219 studies on the registry; 7 are open to participants now.

Of its 49 completed or terminated interventional studies of FDA-regulated products, 41 (84%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

This study will include subjects who meet all of the following inclusion criteria:

  • Voluntarily provide written informed consent
  • ≥18 years of age
  • Subject-reported history of DED OU for at least 6 months
  • Same eye satisfies the criteria for dry eye signs at both screening and baseline/randomization
  • The criteria for dry eye symptoms are met at both screening and baseline/randomization
  • As needed (PRN) or scheduled use of non-prescription (OTC) artificial tear, gels, or lubricants for symptoms of dry eye within the past 30 days
  • Able and willing to follow instructions, including participation in all trial assessments and visits

Exclusion criteria

Exclusion Criteria:

This study will exclude subjects who meet any of the following exclusion criteria (Note: Ocular exclusion criteria are relevant to both eyes, such that meeting a criterion in either eye excludes the subject from the study):

  • Known allergy or sensitivity to any study treatment (or any of its components)
  • Best-corrected visual acuity (BCVA) of 0.7 logarithm of the minimum angle of resolution (logMAR) or worse (50 Early Treatment Diabetic Retinopathy Study [ETDRS] letters; Snellen equivalent score of 20/100 or worse) at Visit 1 (Screening) or Visit 2 (baseline/randomization)
  • Any clinically significant (CS) ocular surface slit-lamp findings at Visit 1 (Screening) or Visit 2 (baseline/randomization), or findings that may interfere with trial parameters in the opinion of the Investigator.
  • Use of any of any ocular therapies within 30 days.
  • Unable or unwilling to stop current topical dry eye treatments

Additional criteria per protocol

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
443 participants (actual)

Study arms

  • Experimental
    Arm 1

    Drug: Lifitegrast/Perfluorohexyloctane Fixed Dose Combination

  • Active comparator
    Arm 2

    Drug: Lifitegrast

  • Active comparator
    Arm 3

    Drug: Perfluorohexyloctane

  • Placebo comparator
    Arm 4

    Drug: Vehicle

  • Placebo comparator
    Arm 5

    Drug: Vehicle

  • Placebo comparator
    Arm 6

    Drug: Vehicle

Interventions

  • DrugLifitegrast/Perfluorohexyloctane Fixed Dose Combination

    Topical ocular drop of lifitegrast and perfluorohexyloctane administered for 4 weeks

  • DrugLifitegrast

    Topical ocular drop of lifitegrast administered for 4 weeks

  • DrugPerfluorohexyloctane

    Topical ocular drop of perfluorohexyloctane administered for 4 weeks

  • DrugVehicle

    Topical ocular drop with no active ingredients administered for 4 weeks

  • DrugVehicle

    Topical ocular drop with no active ingredients administered for 4 weeks

  • DrugVehicle

    Topical ocular drop with no active ingredients administered for 4 weeks

06

What researchers measure

Primary outcomes

  1. Total corneal fluorescein staining change from baseline

    Time frame: Baseline, day 29

07

Study locations

32 sites
  • Eye Doctors of Arizona, PLLC
    Phoenix, Arizona 85028, United States
  • Global Research Management, Inc.
    Glendale, California 91204, United States
  • SoCal Eye - Lakewood Clinic
    Long Beach, California 90805, United States
  • LoBue Laser and Eye Medical Center
    Murrieta, California 92562, United States
  • Eye Research Foundation, Inc.
    Newport Beach, California 92663, United States
  • Wolstan and Goldberg Eye Associates
    Torrance, California 90505, United States
  • Segal Drug Trials/Office of Bruce A Segal, MD
    Delray Beach, Florida 33484, United States
  • Bowden Eye and Associates
    Jacksonville, Florida 32256, United States
  • Shettle Eye Research, Inc
    Largo, Florida 33773, United States
  • Clayton Eye Clinical Research, LLC
    Morrow, Georgia 30260, United States
  • Midwest Cornea Associates LLC
    Carmel, Indiana 46032, United States
  • Kannarr Eye Care, LLC
    Pittsburg, Kansas 66762, United States
  • Vance Thompson Vision - Alexandria
    Alexandria, Minnesota 56308, United States
  • Complete Eye Care of Medina
    Medina, Minnesota 55340, United States
  • Insight Eyecare Specialties, Inc.
    Kansas City, Missouri 64111, United States
  • Moyes Eye Center, P.C.
    Kansas City, Missouri 64154, United States
  • Ophthalmology Consultants, Ltd.
    St Louis, Missouri 63131, United States
  • Comprehensive Eye Care Ltd.
    Washington, Missouri 63090, United States
  • Opthalmic consultants of Long Island
    Garden City, New York 11530, United States
  • Rochester Ophthalmological Group,PC
    Rochester, New York 14618, United States
  • Asheville Eye Associates
    Asheville, North Carolina 28803, United States
  • Oculus Research
    Garner, North Carolina 27529, United States
  • CORE Inc.
    Shelby, North Carolina 28150, United States
  • Vance Thompson Vision - Fargo, ND
    West Fargo, North Dakota 58078, United States
  • Insight Research Clinic LLC.
    Powell, Ohio 43065, United States
  • Scott & Christie Eyecare Associates - The Surgery Center at Cranberry
    Cranberry Township, Pennsylvania 16066, United States
  • West Bay Eye Associates
    Warwick, Rhode Island 02888, United States
  • Southern College of Optometry
    Memphis, Tennessee 38104, United States
  • Total Eye Care PA
    Memphis, Tennessee 38119, United States
  • Advancing Vision Research, LLC
    Smyrna, Tennessee 37167, United States
  • Intouch Clinical Research Center
    Houston, Texas 77034, United States
  • Lake Travis Eye and Laser Center
    Lakeway, Texas 78738, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jul 14, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07128628
Lead sponsor
Bausch & Lomb Incorporated
Responsible party
Sponsor
First posted
Aug 19, 2025
Start date
Oct 24, 2025
Primary completion
May 28, 2026
Completion
May 28, 2026
Last update
Jul 14, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion